A PHASE 3 MULTICENTER RANDOMIZED OPENLABEL ACTIVE-CONTROLLED TRIAL OF DS-8201A AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN S CHOICE FOR HER2LOW UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS



If you are registered as a volunteer, please login to the dashboard to send referrals.